New Haven-based biotech firm Halda Therapeutics secured $126M in Series B extension funding, totaling $202M to date. The funds, raised with participation from leading investors including Deep Track Capital and RA Capital Management, will support the development of Halda’s novel cancer therapies, RIPTACTM therapeutics.